EULAR 2025
Read the full Report (pdf)
European Alliance of Associations for Rheumatology 11–14 June 2025 Barcelona, Spain
Featured articles
EULAR 2025 Highlights Podcast
CONTENTS
Online First
Arthritis in 2025
Preventive abatacept may delay RA diagnosis in at-risk populations
Patients with musculoskeletal pain and ACPA positivity: most progress to arthritis, but not always RA
Spotlight on Spondyloarthritis
Bone marrow oedema in axial spondyloarthritis: different patterns identified
Digital therapeutic Axia enhances outcomes in axial spondyloarthritis
What is New in Lupus, Scleroderma, and Myositis
Combination of rituximab and mycophenolate mofetil offers no superiority over monotherapy in SSc-related ILD
Early clinical events flag systemic sclerosis earlier than the classification criteria
New targeted therapy shows efficacy in inflammatory myopathy
Enpatoran shows encouraging signals in lupus, despite an unmet primary endpoint
Robust renal efficacy with obinutuzumab across key clinical criteria in lupus nephritis
New Developments in Crystal-related Disorders
Targeting serum uric acid pays off: gout strategy cuts MACE
A novel compound emerging as a treatment for refractory gout
Osteoarthritis and Osteoporosis
Initiating glucocorticoids for rheumatic diseases: sequential romosozumab- denosumab treatment increases lumbar BMD
Rapid and clinically meaningful pain relief in knee OA with novel neurotrophin inhibitor
Best of the Posters
Air pollution may increase autoimmune risk through ANA positivity
Weight-bearing exercise contributes to bone health in inflammatory rheumatic diseases
Zasocitinib is efficacious in minimal disease activity and PASI in patients with PsA
Late-Breaking Abstracts
Combination of leflunomide and hydroxychloroquine reduces disease activity in Sjögren’s disease
Guselkumab slows joint damage progression in PsA
